Last reviewed · How we verify
Ritonavir-boosted indinavir
At a glance
| Generic name | Ritonavir-boosted indinavir |
|---|---|
| Sponsor | Harvard School of Public Health (HSPH) |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin (PHASE1, PHASE2)
- Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection (PHASE2)
- Lopinavir/Ritonavir Monotherapy in Children (PHASE4)
- Pharmacokinetic Study of Indinavir Drug Levels When Boosted With Ritonavir in Thailand
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ritonavir-boosted indinavir CI brief — competitive landscape report
- Ritonavir-boosted indinavir updates RSS · CI watch RSS
- Harvard School of Public Health (HSPH) portfolio CI